Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

BACKGROUND: Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK(+) non-smallcell lung cancer (NSCLC) patients to over five years. In particular, second-generation ALK TKI have demonstrated superiority compared to the first-ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Christopoulos, Petros, Bozorgmehr, Farastuk, Brückner, Lena, Chung, Inn, Krisam, Johannes, Schneider, Marc A., Stenzinger, Albrecht, Eickhoff, Regina, Mueller, Daniel W., Thomas, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240323/
https://www.ncbi.nlm.nih.gov/pubmed/34182952
http://dx.doi.org/10.1186/s12885-021-08460-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240323/
https://www.ncbi.nlm.nih.gov/pubmed/34182952
http://dx.doi.org/10.1186/s12885-021-08460-w

Ejemplares similares